WuXi Biologics (Cayman) Inc.

WXIBF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$4,834$3,400$4,420$3,993
Dep. & Amort.$1,437$1,169$801$482
Deferred Tax$0$0$0-$567
Stock-Based Comp.$1,216$1,274$1,297$532
Change in WC-$801-$896-$974-$963
Other Non-Cash-$1,469-$279-$2-$45
Operating Cash Flow$5,217$4,668$5,542$3,431
Investing Activities
PP&E Inv.-$3,930-$4,046-$5,868-$6,523
Net Acquisitions$0$0-$131-$2,535
Inv. Purchases-$11,429-$15,083-$10,771-$59,300
Inv. Sales/Matur.$10,893$15,638$10,485$58,244
Other Inv. Act.$524$262$378$513
Investing Cash Flow-$3,942-$3,228-$5,908-$9,602
Financing Activities
Debt Repay.$490-$818-$295-$147
Stock Issued$19$26$36$11,035
Stock Repurch.-$1,766-$917-$2,804-$2,517
Dividends Paid$0$0$0$0
Other Fin. Act.-$1,494$3,670$472-$162
Financing Cash Flow-$2,750$1,961-$2,592$8,209
Forex Effect$84-$126$350-$132
Net Chg. in Cash-$1,391$3,275-$2,608$1,908
Supplemental Information
Beg. Cash$9,670$6,395$9,003$7,096
End Cash$8,279$9,670$6,395$9,003
Free Cash Flow$1,288$437-$327-$3,092